Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
PD-1
Biotech
Pfizer ties PD-1 drug to 32% cancer risk reduction in phase 3
The study fell short of a clean sweep, with Pfizer finding no effect on survival and seeing a higher rate of serious adverse events in the PD-1 arm.
Nick Paul Taylor
Apr 28, 2025 7:25am
AnaptysBio's PD-1 drug reduces rheumatoid arthritis in phase 2
Feb 12, 2025 9:57am
Will Novartis catch the PD-1 bispecific wave? CEO weighs in
Jan 31, 2025 3:30am
Pfizer's PD-1 prospect hits goal in phase 3 bladder cancer study
Jan 10, 2025 6:45am
Ottimo raises $140M to ready PD1/VEGFR2 antibody for clinic
Dec 19, 2024 6:58am
HanxBio plans Hong Kong IPO to fund phase 2 solid tumor trial
Nov 25, 2024 9:20am
